Tritiated thymidine labeling index and response in human breast cancer

A. Sulkes, Robert B Livingston, W. K. Murphy

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Tumor cell uptake of tritiated thymidine, expressed as the labelling index (LI), was determined prior to treatment of 25 patients with disseminated breast carcinoma. All patients subsequently received combination chemotherapy with adriamycin, cyclophosphamide, and an antimetabolite (usually 5-fluorouracil), with or without vincristine. The LI was significantly higher in responders to chemotherapy than in nonresponders (mean, 15 vs. 7.1; P < 0.01). Other pretreatment variables examined did not show a significant association with likelihood of response. Measurements of the tumor cell LI in patients with accessible tumor may be of benefit in selection of treatment; 0 of 9 patients with an LI less than 9 had a response in our series in contrast to 11 of 16 patients with an LI greater than 9 who had a response (P = 0.001).

Original languageEnglish (US)
Pages (from-to)513-515
Number of pages3
JournalJournal of the National Cancer Institute
Volume62
Issue number3
StatePublished - 1979
Externally publishedYes

Fingerprint

Thymidine
Breast Neoplasms
Antimetabolites
Neoplasms
Vincristine
Combination Drug Therapy
Fluorouracil
Doxorubicin
Cyclophosphamide
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tritiated thymidine labeling index and response in human breast cancer. / Sulkes, A.; Livingston, Robert B; Murphy, W. K.

In: Journal of the National Cancer Institute, Vol. 62, No. 3, 1979, p. 513-515.

Research output: Contribution to journalArticle

@article{bca5c7892d2146258e21a4c61d6efe89,
title = "Tritiated thymidine labeling index and response in human breast cancer",
abstract = "Tumor cell uptake of tritiated thymidine, expressed as the labelling index (LI), was determined prior to treatment of 25 patients with disseminated breast carcinoma. All patients subsequently received combination chemotherapy with adriamycin, cyclophosphamide, and an antimetabolite (usually 5-fluorouracil), with or without vincristine. The LI was significantly higher in responders to chemotherapy than in nonresponders (mean, 15 vs. 7.1; P < 0.01). Other pretreatment variables examined did not show a significant association with likelihood of response. Measurements of the tumor cell LI in patients with accessible tumor may be of benefit in selection of treatment; 0 of 9 patients with an LI less than 9 had a response in our series in contrast to 11 of 16 patients with an LI greater than 9 who had a response (P = 0.001).",
author = "A. Sulkes and Livingston, {Robert B} and Murphy, {W. K.}",
year = "1979",
language = "English (US)",
volume = "62",
pages = "513--515",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Tritiated thymidine labeling index and response in human breast cancer

AU - Sulkes, A.

AU - Livingston, Robert B

AU - Murphy, W. K.

PY - 1979

Y1 - 1979

N2 - Tumor cell uptake of tritiated thymidine, expressed as the labelling index (LI), was determined prior to treatment of 25 patients with disseminated breast carcinoma. All patients subsequently received combination chemotherapy with adriamycin, cyclophosphamide, and an antimetabolite (usually 5-fluorouracil), with or without vincristine. The LI was significantly higher in responders to chemotherapy than in nonresponders (mean, 15 vs. 7.1; P < 0.01). Other pretreatment variables examined did not show a significant association with likelihood of response. Measurements of the tumor cell LI in patients with accessible tumor may be of benefit in selection of treatment; 0 of 9 patients with an LI less than 9 had a response in our series in contrast to 11 of 16 patients with an LI greater than 9 who had a response (P = 0.001).

AB - Tumor cell uptake of tritiated thymidine, expressed as the labelling index (LI), was determined prior to treatment of 25 patients with disseminated breast carcinoma. All patients subsequently received combination chemotherapy with adriamycin, cyclophosphamide, and an antimetabolite (usually 5-fluorouracil), with or without vincristine. The LI was significantly higher in responders to chemotherapy than in nonresponders (mean, 15 vs. 7.1; P < 0.01). Other pretreatment variables examined did not show a significant association with likelihood of response. Measurements of the tumor cell LI in patients with accessible tumor may be of benefit in selection of treatment; 0 of 9 patients with an LI less than 9 had a response in our series in contrast to 11 of 16 patients with an LI greater than 9 who had a response (P = 0.001).

UR - http://www.scopus.com/inward/record.url?scp=0018377254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018377254&partnerID=8YFLogxK

M3 - Article

C2 - 283280

AN - SCOPUS:0018377254

VL - 62

SP - 513

EP - 515

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -